APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA) Meeting Abstract


Authors: Tempero, M. A.; Cardin, D. B.; Biankin, A.; Goldstein, D.; Moore, M.; O'Reilly, E. M.; Philip, P. A.; Riess, H.; Macarulla, T.; Yung, L.; Wei, X. Y.; Lu, B.
Abstract Title: APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA)
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613202111
PROVIDER: wos
Notes: Meeting Abstract: TPS4162^ -- Source: Wos